drugset / Trial / NCT02601378
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
Timeline
- Start
- 2016-02-01
- Primary completion
- 2022-01-07
- Completion
- 2022-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darovasertib | Small molecule | — | Oral |
| Subject | Siremadlin | Small molecule | — | — |